Further Declines in Lithium-Ion Battery Costs Expected


Source: MIT Researchers

Study Reveals Plunge in Lithium-ion Battery Costs

 

David L. Chandler | MIT News Office

 

The cost of the rechargeable lithium-ion batteries used for phones, laptops, and cars has fallen dramatically over the last three decades and has been a major driver of the rapid growth of those technologies. But attempting to quantify that cost decline has produced ambiguous and conflicting results that have hampered attempts to project the technology’s future or devise useful policies and research priorities.

Now, MIT researchers have carried out an exhaustive analysis of the studies that have looked at the decline in the prices of these batteries, which are the dominant rechargeable technology in today’s world. The new study looks back over three decades, including analyzing the original underlying datasets and documents whenever possible, to arrive at a clear picture of the technology’s trajectory.

The researchers found that the cost of these batteries has dropped by 97 percent since they were first commercially introduced in 1991. This rate of improvement is much faster than many analysts had claimed and is comparable to that of solar photovoltaic panels, which some had considered to be an exceptional case. The new findings are reported today in the journal Energy and Environmental Science, in a paper by MIT postdoc Micah Ziegler and Associate Professor Jessika Trancik.

While it’s clear that there have been dramatic cost declines in some clean-energy technologies such as solar and wind, Trancik says, when they started to look into the decline in prices for lithium-ion batteries, “we saw that there was substantial disagreement as to how quickly the costs of these technologies had come down.” Similar disagreements showed up in tracing other important aspects of battery development, such as the ever-improving energy density (energy stored within a given volume) and specific energy (energy stored within a given mass).

“These trends are so consequential for getting us to where we are right now, and also for thinking about what could happen in the future,” says Trancik, who is an associate professor in MIT’s Institute for Data, Systems and Society. While it was common knowledge that the decline in battery costs was an enabler of the recent growth in sales of electric vehicles, for example, it was unclear just how great that decline had been. Through this detailed analysis, she says, “we were able to confirm that yes, lithium-ion battery technologies have improved in terms of their costs, at rates that are comparable to solar energy technology, and specifically photovoltaic modules, which are often held up as kind of the gold standard in clean energy innovation.”

It may seem odd that there was such great uncertainty and disagreement about how much lithium-ion battery costs had declined and what factors accounted for it, but in fact, much of the information is in the form of closely held corporate data that is difficult for researchers to access. Most lithium-ion batteries are not sold directly to consumers — you can’t run down to your typical corner drugstore to pick up a replacement battery for your iPhone, your PC, or your electric car. Instead, manufacturers buy lithium-ion batteries and build them into electronics and cars. Large companies like Apple or Tesla buy batteries by the millions, or manufacture them themselves for prices that are negotiated or internally accounted for but never publicly disclosed.

In addition to helping to boost the ongoing electrification of transportation, further declines in lithium-ion battery costs could potentially also increase the batteries’ usage in stationary applications as a way of compensating for the intermittent supply of clean energy sources such as solar and wind. Both applications could play a significant role in helping to curb the world’s emissions of climate-altering greenhouse gases. “I can’t overstate the importance of these trends in clean energy innovation for getting us to where we are right now, where it starts to look like we could see rapid electrification of vehicles and we are seeing the rapid growth of renewable energy technologies,” Trancik says. “Of course, there’s so much more to do to address climate change, but this has really been a game-changer.”

The new findings are not just a matter of retracing the history of battery development but of helping to guide the future, Ziegler points out. Combing through all of the published literature on the subject of the cost reductions in lithium-ion cells, he found “very different measures of the historical improvement. And across a variety of different papers, researchers were using these trends to make suggestions about how to further reduce costs of lithium-ion technologies or when they might meet cost targets.” But because the underlying data varied so much, “the recommendations that the researchers were making could be quite different.” Some studies suggested that lithium-ion batteries would not fall in cost quickly enough for certain applications, while others were much more optimistic. Such differences in data can ultimately have a real impact on the setting of research priorities and government incentives.

The researchers dug into the original sources of the published data, in some cases finding that certain primary data had been used in multiple studies that were later cited as separate sources or that the original data sources had been lost along the way. And while most studies have focused only on the cost, Ziegler says it became clear that such a one-dimensional analysis might underestimate how quickly lithium-ion technologies improved; in addition to cost, weight and volume are also key factors for both vehicles and portable electronics. So, the team added a second track to the study, analyzing the improvements in these parameters as well.

“Lithium-ion batteries were not adopted because they were the least expensive technology at the time,” Ziegler says. “There were less expensive battery technologies available. Lithium-ion technology was adopted because it allows you to put portable electronics into your hand, because it allows you to make power tools that last longer and have more power, and it allows us to build cars” that can provide adequate driving range. “It felt like just looking at dollars per kilowatt-hour was only telling part of the story,” he says.

That broader analysis helps to define what may be possible in the future, he adds: “We’re saying that lithium-ion technologies might improve more quickly for certain applications than would be projected by just looking at one measure of performance. By looking at multiple measures, you get essentially a clearer picture of the improvement rate, and this suggests that they could maybe improve more rapidly for applications where the restrictions on mass and volume are relaxed.”

Trancik adds the new study can play an important role in energy-related policymaking. “Published data trends on the few clean technologies that have seen major cost reductions over time, wind, solar, and now lithium-ion batteries, tend to be referenced over and over again, and not only in academic papers but in policy documents and industry reports,” she says. “Many important climate policy conclusions are based on these few trends. For this reason, it is important to get them right. There’s a real need to treat the data with care, and to raise our game overall in dealing with technology data and tracking these trends.”

“Battery costs determine price parity of electric vehicles with internal combustion engine vehicles,” says Venkat Viswanathan, an associate professor of mechanical engineering at Carnegie Mellon University, who was not associated with this work. “Thus, projecting battery cost declines is probably one of the most critical challenges in ensuring an accurate understanding of adoption of electric vehicles.”

Viswanathan adds that “the finding that cost declines may occur faster than previously thought will enable broader adoption, increasing volumes, and leading to further cost declines. … The datasets curated, analyzed and released with this paper will have a lasting impact on the community.”

 

Suggested Reading



Sony Announces Electric Vehicle Division



Lithium Recycling is an EV Opportunity Not Yet on Many Investors’ Radar





How Does Uranium Fit Into the ESG Energy Landscape?



Why Gain of Function Research is Being Conducted

 

 

 

Stay up to date. Follow us:

 

Seanergy Maritime (SHIP) – Convert Debt Buy Backs Reduce Potential Equity Issuance

Thursday, January 20, 2022

Seanergy Maritime (SHIP)
Convert Debt Buy Backs Reduce Potential Equity Issuance

Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. Upon delivery of the M/V Dukeship, the Company’s operating fleet will consist of 17 Capesize vessels with an average age of 11.5 years and aggregate cargo carrying capacity of approximately 3,011,083 dwt. The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP”, its Class A warrants under “SHIPW” and its Class B warrants under “SHIPZ”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    New buy back program of $10.0 million half way done. Convert debt of $5.0 million has been bought back at par. Non-cash charge of ~$1.5 million will hit 1Q2022 numbers. Buy back reduces potential share issuance and fully diluted share count drops by ~4.2 million since conversion price was $1.20/share.

    Capital Link webinar today at 10am EST likely to highlight substantial progress last year.  Well positioned entering this year due to fleet expansion, debt financings, 1Q2021 equity offering and January debt restructuring. In addition, the $22 million buy back program to date, is a solid example of better execution and improving financials …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Voyager Digital CEO Withdraws Automatic Securities Disposition Plan

 



Voyager Digital CEO Withdraws Automatic Securities Disposition Plan

Research, News, and Market Data on Voyager Digital

 

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQB: VYGVF; FRA: UCD2) one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced that Stephen Ehrlich, CEO and Director, has withdrawn the automatic securities disposition plan (“ASDP”) that was previously announced on December 31, 2021. No shares have been sold under the plan. The ASDP will, in accordance with its terms, terminate 30 days from the date of this press release.
 
Commenting on the withdrawal, Mr. Ehrlich noted, “Despite having a floor significantly above the current stock price, I felt it was in the best interest of the investors to withdraw the plan.” Ehrlich continued, “Based on our key financial metrics, including revenues for the quarter ended December 31, 2021 as disclosed in our press release issued January 5, 2022, I believe Voyager is undervalued and am excited about our product growth and expanded capabilities planned for 2022, including our NFT offering, debit card rollout, international expansion and more.
 
About Voyager Digital Ltd.

Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQB: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different cryptocurrency assets using its easy-to-use mobile application and earn rewards up to 12% annually on more than 35 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides cryptocurrency payment solutions for both consumers and merchants around the globe.

To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

SOURCE Voyager Digital, Ltd.

Press Contacts

Voyager Digital, Ltd.

Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

Wall Street’s Tools to Copycat Meme Stock Investor Successes


Is it Game-Over for Meme Stock Investors?

 

The tide turned about a year ago.  Professional traders scoffed at the activity they were witnessing in presumed “dead” stocks.  GameStop (GME), AMC Theaters (AMC), both skyrocketing.  Even presumed pandemic nightmare companies such as Hertz (HTZ), international bulk carrier Seanergy (SHIP), and  Norwegian Cruise Lines (NCLH) saw unexpected
buy interest
from self-directed investors.  TV pundits discussed how the retail traders placing these trades were going to get wiped out.  Meanwhile, retail’s combined activity hurt the value of a few powerful funds, notably those that had massive shorts in some of these companies.  Their activity even caused retail brokers like E*Trade (MS) and Robinhood (HOOD) to
halt
some activities
in the popular retail shares.  It used to be that small investors tried to mimic the professionals.  Now, tools are being created so the big guys can monitor communication, sentiment, and activity on social media platforms such as Reddit, Twitter (TWTR), and Stocktwits.

Money Flows

Economics 101 tells us prices move up when demand increases with unchanged supply.  This is just as true for stocks as it is for Gold,
oil, or even tulip
bulbs
.  By the same math, there are worthwhile companies whose value is not yet recognized that would likely be priced higher with more attention.  And companies with extremely unpredictable tomorrows that, if the masses all moved to buy at once, would surely see a price increase.  

A number of hedge funds that underestimated the tenacity of the r/wallstreetbets traders, were resolved to hold their short positions while the retail demand was increasing.  In the end, it’s calculated that managed funds lost $20 billion in this Davey vs. Goliath match-up.

These money flows, possibly even stimulus
check
 funded accounts, “left a mark” on institutional investors.  No previous experience or education prepared them for this phenomenon.  Prices of fallen-from-favor household name stocks were soaring by hundreds of a percent.  Their experience instead indicated they should side against the amateurs.

 

Change of Thinking

As it became widely known that retail traders or amateur investors plotting on social media and message boards were capable of running-up stocks or commodities, the pros took a “game-on” stance.  It was a game they didn’t win, beaten down companies like GameStop rose 2,000% in the face of pros shorting the stock.

 

“If enough people with enough money start valuing stocks a different way, their new metrics matter, too, even if you think they’re absurd,” – Jim Kramer, discussing the climb in Wendy’s (WND) shares, June 8, 2021.

 

After almost a year, professionals are recognizing that the market’s climate has changed, and they should amass the tools they need to combat the new environment.  A company called Sentifi, with the tagline “Better Investments With Collective
Intelligence,”
has just signed a deal to provide “alternative data” to Morningstar.  The company keeps track of hundreds of millions of messages across social media websites like Twitter and Reddit.  It observes shifts in chatter that can help predict which companies or assets are about to soar or plummet.  Morningstar which is one of the most broadly followed investment analytics providers will be integrating Sentifi’s sentiment and attentive analytics into its products as an additional toolset.  The intent is to provide users, including fund managers, financial advisors, and other investors, a means to keep pace with market shifts and price signals.  The expectation is to uncover shifts in sentiment early, discern investment opportunities and risks inherent in the changes.  

While Morningstar is integrating Sentifi into its product line, many other companies, particularly hedge funds, began to rely on its analysis last year.  Other large firms have built their own data gathering information systems.  At UBS, analysts now monitor retail trading activity; in-house traders use the information as one of their decision-making tools.  The investment bank directly tracks retail flows and volumes, analyzes options activity, and monitors social-media sentiment to determine the strength of what self-directed investors may be doing.  Keith Parker is the head of US equity strategy at UBS, he has said, “For the most part, retail doesn’t impact or traffic in tons of stocks.  But the ones that they do, they tend to have pretty outsized influence.  And so it does matter at the extremes.”

 

Take-Away

As the expression goes, kill or be killed.  As the markets evolve, so must the players in order to continue to interact with the market.  An increasing number of professionals are not just taking retail stock market activity seriously; they are committed to benefitting from it.  The benefit can be both offensive and defensive.  It remains to be seen if the offensive plays that could be categorized as joining with the retail action will induce even more pronounced swings, but it is clear that information is readily available to them as the so-called meme stock investors are effectively writing their plays out where they can be seen and studied.  Their tactics may need to be altered.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



You Can Own a Piece of r/WallStreetBets



Tulip Mania Compared to Cryptocurrencies and Meme Stock Investing





Short-Sellers Vs. GameStop Buyers



Are Meme Stocks Improving Flawed Markets?

 

 

Sources

https://www.youtube.com/watch?v=aSUuB4cLWPU

https://www.morningstar.com/news/business-wire/20211208005489/sentifi-announces-addition-of-alternative-data-into-morningstar-data-products

 

Stay up to date. Follow us:

 

Palladium One Reports Infill Drill Results Between the Kaukua Open Pit Resource and Kaukua South, Finland



Palladium One Reports Infill Drill Results Between the Kaukua Open Pit Resource and Kaukua South, Finland

Research, News, and Market Data on Palladium One Mining

 

January 20, 2021 – Toronto, Ontario. Infill drilling in the Gap Zone has resulted in a better understanding and a new geological model for the area. Gap Zone drill results include 2.2 g/t Pd_Eq over 4.4 meters, within 1.3 g/t Pd_Eq over 21.6 meters, in hole LK21-209 starting at 138 meters down hole (Figure 1), said Palladium One Mining Inc. (“Palladium One” or the “Company”).

Derrick Weyrauch, President and CEO commented: “We have made significant progress infilling the area between the Kaukua Open Pit Resource and Kaukua South. Though Gap Zone mineralization is thinner, it could play a significant role in joining Kaukua and Kaukua South into one larger and more efficient Open Pit mine.”

The Greater Kaukau area is now subdivide into three blocks separated by northeast trending faults (Figure 1, 2 and 3), Kaukua Open Pit, Gap Zone, and Kaukua South. These blocks though closely related geologically, differ in their orientation, and thickness of mineralization. Kaukua Open Pit and Kaukua South both dip to the south and posses core zones with thickness in excess of 100 meters, whereas the Gap Zone, which dips west, demonstrates mineralization thicknesses in the 10-20 meter range. All three fault blocks contain Upper Zone mineralization while the width separating the Upper and Lower Zones varies in each fault block.

Figure 1. Historic and current drilling in the Kaukua area having a drill data cut-off date of September 30, 2021 (hole LK21-137), assays have been received for holes up to LK21-120, the remainder are pending. Background is Induced Polarization (“IP”) Chargeability.


Figure 2. Cross sections showing holes LK21- 112, 113, 114, 117 and LK20-042 in Kaukua South and Gap Zone.


Figure 3. Inclined Isometric view looking north of the 3D geological model of the Greater Kaukua Area showing the >0.3g/t Pd_Eq wireframe shell (purple) as well as major later dykes and faults separating the Kaukua, Gap, and Kaukua South Zones.All drill holes, historic and those drilled by the Company are shown in black.


Table 1. LK Project, select Kaukua Drill Hole Results


* Pd_Eq calculated using in-situ values and prices from the 2021 NI43-101 Haukiaho Mineral Resource Estimate; $1,600/oz Pd, $1,100/oz Pt, $1,650/oz Au, $3.50 Cu, and $7.50/lb Ni, and $20/lb Co. Limited historical metallurgical work on the Kaukua Deposit indicates final recoveries in the range of 73% Pd, 56% Pt, 78% Au, 91% Cu, 48% Ni and 48% Co and are used in the Estimated Recovered Pd_Eq grade calculation.

Palladium Equivalent

The Company is calculating Palladium equivalent using US$1,600 per ounce for palladium, US$1,100 per ounce for platinum, US$1,650 per ounce for gold, US$3.50 per pound for copper, US$7.50 per pound for nickel, and $20 per pound cobalt consistent with the calculation used in the Company’s September 2021 NI 43-101 Haukiaho Resource Estimate.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101

About Palladium One

Palladium One Mining Inc. (TSXV: PDM) is focused on discovering environmentally and socially conscious Metals for Green Transportation. A Canadian mineral exploration and development company, Palladium One is targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in leading mining jurisdictions. Its flagship project is the Läntinen Koillismaa (LK) Project in north-central Finland, which is ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. LK is a PGE-copper-nickel project that has existing Mineral Resources. PDM’s second project is the 2020 Discovery of the Year Award winning Tyko Project, a high-grade sulphide, copper-nickel project located in Canada. Follow Palladium One on LinkedInTwitter, and at www.palladiumoneinc.com.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Neovasc Announces Publication Supporting the Neovasc Reducer Device



Neovasc Announces Publication Supporting the Neovasc Reducer Device

Research, News, and Market Data on Neovasc

 

VANCOUVER and MINNEAPOLIS – ( NewMediaWire ) – January 20, 2022 –  Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced the publication of an article entitled, The Effectiveness of CS Reducer for the Treatment of Refractory Angina a Meta-Analysis in the Canadian Journal of Cardiology.

The articles lead author and senior authors are Aviram Hochstadt, M.D., and Maayan Konigstein, M.D., Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The publication provides a meta-analysis assessing the effects of coronary sinus narrowing in a total of 846 patients across nine prospective studies. The primary outcome was the proportion of patients improving 1 class in the Canadian Cardiovascular Society (CSS) angina score.

Improvement of 1 CSS class occurred in 76% (95% CI 73%-80%) of patients. Improvement of 2 CSS classes was observed in 40% of patients (95% CI of 35-46%). Procedure success was 98%, with no major and 3% minor peri-procedural complications. Patients walking distances, as measured by the six-minute walk test, also significantly improved.

The authors concluded, This meta-analysis of clinical studies describing the outcomes of patients with refractory angina implanted with the Reducer for CS narrowing, demonstrates its safety and efficacy. The vast majority of patients experienced improvement in angina severity, quality of life, and functional performance.

“Publication of this meta-analysis is another meaningful milestone for the Reducer,” stated Fred Colen, President & Chief Executive Officer of Neovasc. “From the very beginning, our company has focused on developing high-quality data to support the adoption of the therapy. As the evidence supporting the safety and effectiveness continues to mount, we are seeing continued expansion of the technology in the marketplace. We look forward to sharing our Q4 2021 results and providing further details of our COSIRA-II randomized controlled trial on our upcoming earnings call.”

About Reducer

The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives because of their disabling symptoms. The Reducer is designed to alter blood flow within the myocardium of the heart and increase the perfusion of oxygenated blood to ischemic areas of the heart muscle, which may provide relief of angina symptoms.

While the Reducer is not approved for commercial use in the United States, the FDA has granted Breakthrough Device designation to the Reducer. This designation is granted by the FDA to prioritize review of subsequent regulatory submissions for a device that demonstrates compelling potential to provide a more effective treatment of a life-threatening or irreversibly debilitating disease, represents breakthrough technology for which no approved alternatives exist or offers significant advantages over existing alternatives, and the availability of which is in the best interest of patients.

Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com .

Contacts

Investors:

Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media:

Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the significance of the meta-analysis for the Reducer, anticipated timelines regarding the provision of Q4 2021 results and details on the COSIRA-II trial, the growing incidence of refractory angina and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company’s ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company’s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company’s expected schedule; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company’s common shares (the “Common Shares”) may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; the Company’s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company’s products; risks relating to health and safety concerns associated with the Company’s products and industry; risks relating to the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; risks relating to the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company’s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company’s shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2021 (copies of which may be obtained atorwww.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether because of new information, future events or otherwise, except as required by law. www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether because of new information, future events or otherwise, except as required by law.

Digerati Technologies (DTGI) – A Discussion: Candid & Insightful

Thursday, January 20, 2022

Digerati Technologies (DTGI)
A Discussion: Candid & Insightful

Digerati Technologies, Inc. (OTCQB: DTGI) is a telecom and technology provider of diverse, carrier-grade, Only in the Cloud™ communication and network solutions including Unified Communication as a Service, cloud telephony, cloud WAN, cloud call center, cloud mobile, and delivery of digital oxygen on its fiber/mobile broadband network. Digerati has developed a robust integration platform to fuel mergers and acquisitions in a highly fragmented market as it delivers flexible, cost-effective services with enterprise-grade quality and reliability. A multi-year recipient of Deloitte’s Fast500 and Fast50 Awards for one of the fastest growing technology companies in North America, Digerati has become an expert at successfully merging and managing subsidiary operations since 2015. The Company’s impressive tech-stack serves 28,000 business users on its platform and its dynamic channel program includes over 300 channel partners that serve as a conduit for sales growth. Digerati has continuously increased customer adoption while serving diverse industries including Healthcare, Banking, Financial Services, Legal, Real Estate, and Construction. Digerati currently has a strong platform for growth throughout Texas and Florida, the 2nd and 4th largest state economies by GDP in the U.S. The Company’s clean and clear fundamentals, combined with its clearly defined growth plan, disciplined acquisition strategy and seasoned leadership team is expected to increase shareholder value as it enters the next phase of its corporate development plan. For more information, please visit www.digerati-inc.com.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    C-suite interview highlights. This report highlights a C-Suite interview with Digerati’s CEO, Arthur Smith. The video can be found by clicking here. Some of the topics covered in the discussion include the macroeconomic environment and the affects on the company; Digerati’s capabilities in serving many different types of customers; the company’s acquisition strategy; and a timely discussion on a recent acquisition in the growing market of Texas.

    Holding up to economic headwinds.  Management does not believe demand for the company’s services has been affected by current economic headwinds, such as inflation and weakened consumer confidence. Although the ongoing supply chain disruptions have impacted the availability of some of the company’s products, Digerati has the technological flexibility to adjust its hardware solutions, when necessary …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Neovasc Announces Publication Supporting the Neovasc Reducer Device



Neovasc Announces Publication Supporting the Neovasc Reducer Device

Research, News, and Market Data on Neovasc

 

VANCOUVER and MINNEAPOLIS – ( NewMediaWire ) – January 20, 2022 –  Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced the publication of an article entitled, The Effectiveness of CS Reducer for the Treatment of Refractory Angina a Meta-Analysis in the Canadian Journal of Cardiology.

The articles lead author and senior authors are Aviram Hochstadt, M.D., and Maayan Konigstein, M.D., Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. The publication provides a meta-analysis assessing the effects of coronary sinus narrowing in a total of 846 patients across nine prospective studies. The primary outcome was the proportion of patients improving 1 class in the Canadian Cardiovascular Society (CSS) angina score.

Improvement of 1 CSS class occurred in 76% (95% CI 73%-80%) of patients. Improvement of 2 CSS classes was observed in 40% of patients (95% CI of 35-46%). Procedure success was 98%, with no major and 3% minor peri-procedural complications. Patients walking distances, as measured by the six-minute walk test, also significantly improved.

The authors concluded, This meta-analysis of clinical studies describing the outcomes of patients with refractory angina implanted with the Reducer for CS narrowing, demonstrates its safety and efficacy. The vast majority of patients experienced improvement in angina severity, quality of life, and functional performance.

“Publication of this meta-analysis is another meaningful milestone for the Reducer,” stated Fred Colen, President & Chief Executive Officer of Neovasc. “From the very beginning, our company has focused on developing high-quality data to support the adoption of the therapy. As the evidence supporting the safety and effectiveness continues to mount, we are seeing continued expansion of the technology in the marketplace. We look forward to sharing our Q4 2021 results and providing further details of our COSIRA-II randomized controlled trial on our upcoming earnings call.”

About Reducer

The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. It affects millions of patients worldwide, who typically lead severely restricted lives because of their disabling symptoms. The Reducer is designed to alter blood flow within the myocardium of the heart and increase the perfusion of oxygenated blood to ischemic areas of the heart muscle, which may provide relief of angina symptoms.

While the Reducer is not approved for commercial use in the United States, the FDA has granted Breakthrough Device designation to the Reducer. This designation is granted by the FDA to prioritize review of subsequent regulatory submissions for a device that demonstrates compelling potential to provide a more effective treatment of a life-threatening or irreversibly debilitating disease, represents breakthrough technology for which no approved alternatives exist or offers significant advantages over existing alternatives, and the availability of which is in the best interest of patients.

Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, is estimated to affect 600,000 to 1.8 million Americans, with 50,000 to 100,000 new cases per year.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™ for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com .

Contacts

Investors:

Mike Cavanaugh
ICR Westwicke
Phone: +1.617.877.9641
Email: Mike.Cavanaugh@westwicke.com

Media:

Sean Leous
ICR Westwicke
Phone: +1.646.866.4012
Email: Sean.Leous@westwicke.com

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend,” “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the significance of the meta-analysis for the Reducer, anticipated timelines regarding the provision of Q4 2021 results and details on the COSIRA-II trial, the growing incidence of refractory angina and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company’s ability to continue as a going concern; risks related to the recent COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company’s operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company’s expected schedule; risks relating to the Company’s need for significant additional future capital and the Company’s ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company’s common shares (the “Common Shares”) may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s conclusion that it did have effective internal control over financial reporting as of December 31, 2020 but not at December 31, 2019 and 2018; risks relating to the Common Share price being volatile; risks relating to the possibility that the Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company’s significant indebtedness, and its effect on the Company’s financial condition; risks relating to lawsuits that the Company is subject to, which could divert the Company’s resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company’s ability to establish, maintain and defend intellectual property rights in the Company’s products; risks relating to results from clinical trials of the Company’s products, which may be unfavorable or perceived as unfavorable; the Company’s history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company’s products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company’s ability to achieve or maintain expected levels of market acceptance for the Company’s products, as well as the Company’s ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company’s ability to convince public payors and hospitals to include the Company’s products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company’s products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company’s products; risks relating to health and safety concerns associated with the Company’s products and industry; risks relating to the Company’s manufacturing operations, including the regulation of the Company’s manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company’s products; risks relating to the manufacturing capacity of third-party manufacturers for the Company’s products, including risks of supply interruptions impacting the Company’s ability to manufacture its own products; risks relating to the Company’s dependence on limited products for substantially all of the Company’s current revenues; risks relating to the Company’s exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a “passive foreign investment company”; risks relating to breaches of anti-bribery laws by the Company’s employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company’s dependence upon key personnel to achieve its business objectives; risks relating to the Company’s ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company’s management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company’s ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company’s officers and directors as a result of their involvement with other issuers; and risks relating to anti-takeover provisions in the Company’s constating documents which could discourage a third-party from making a takeover bid beneficial to the Company’s shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Information Form and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2021 (copies of which may be obtained atorwww.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether because of new information, future events or otherwise, except as required by law. www.sedar.com or www.sec.gov). The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether because of new information, future events or otherwise, except as required by law.

Release – Palladium One Reports Infill Drill Results Between the Kaukua Open Pit Resource and Kaukua South Finland



Palladium One Reports Infill Drill Results Between the Kaukua Open Pit Resource and Kaukua South, Finland

Research, News, and Market Data on Palladium One Mining

 

January 20, 2021 – Toronto, Ontario. Infill drilling in the Gap Zone has resulted in a better understanding and a new geological model for the area. Gap Zone drill results include 2.2 g/t Pd_Eq over 4.4 meters, within 1.3 g/t Pd_Eq over 21.6 meters, in hole LK21-209 starting at 138 meters down hole (Figure 1), said Palladium One Mining Inc. (“Palladium One” or the “Company”).

Derrick Weyrauch, President and CEO commented: “We have made significant progress infilling the area between the Kaukua Open Pit Resource and Kaukua South. Though Gap Zone mineralization is thinner, it could play a significant role in joining Kaukua and Kaukua South into one larger and more efficient Open Pit mine.”

The Greater Kaukau area is now subdivide into three blocks separated by northeast trending faults (Figure 1, 2 and 3), Kaukua Open Pit, Gap Zone, and Kaukua South. These blocks though closely related geologically, differ in their orientation, and thickness of mineralization. Kaukua Open Pit and Kaukua South both dip to the south and posses core zones with thickness in excess of 100 meters, whereas the Gap Zone, which dips west, demonstrates mineralization thicknesses in the 10-20 meter range. All three fault blocks contain Upper Zone mineralization while the width separating the Upper and Lower Zones varies in each fault block.

Figure 1. Historic and current drilling in the Kaukua area having a drill data cut-off date of September 30, 2021 (hole LK21-137), assays have been received for holes up to LK21-120, the remainder are pending. Background is Induced Polarization (“IP”) Chargeability.


Figure 2. Cross sections showing holes LK21- 112, 113, 114, 117 and LK20-042 in Kaukua South and Gap Zone.


Figure 3. Inclined Isometric view looking north of the 3D geological model of the Greater Kaukua Area showing the >0.3g/t Pd_Eq wireframe shell (purple) as well as major later dykes and faults separating the Kaukua, Gap, and Kaukua South Zones.All drill holes, historic and those drilled by the Company are shown in black.


Table 1. LK Project, select Kaukua Drill Hole Results


* Pd_Eq calculated using in-situ values and prices from the 2021 NI43-101 Haukiaho Mineral Resource Estimate; $1,600/oz Pd, $1,100/oz Pt, $1,650/oz Au, $3.50 Cu, and $7.50/lb Ni, and $20/lb Co. Limited historical metallurgical work on the Kaukua Deposit indicates final recoveries in the range of 73% Pd, 56% Pt, 78% Au, 91% Cu, 48% Ni and 48% Co and are used in the Estimated Recovered Pd_Eq grade calculation.

Palladium Equivalent

The Company is calculating Palladium equivalent using US$1,600 per ounce for palladium, US$1,100 per ounce for platinum, US$1,650 per ounce for gold, US$3.50 per pound for copper, US$7.50 per pound for nickel, and $20 per pound cobalt consistent with the calculation used in the Company’s September 2021 NI 43-101 Haukiaho Resource Estimate.

Qualified Person

The technical information in this release has been reviewed and verified by Neil Pettigrew, M.Sc., P. Geo., Vice President of Exploration and a director of the Company and the Qualified Person as defined by National Instrument 43-101

About Palladium One

Palladium One Mining Inc. (TSXV: PDM) is focused on discovering environmentally and socially conscious Metals for Green Transportation. A Canadian mineral exploration and development company, Palladium One is targeting district scale, platinum-group-element (PGE)-copper-nickel deposits in leading mining jurisdictions. Its flagship project is the Läntinen Koillismaa (LK) Project in north-central Finland, which is ranked by the Fraser Institute as one of the world’s top countries for mineral exploration and development. LK is a PGE-copper-nickel project that has existing Mineral Resources. PDM’s second project is the 2020 Discovery of the Year Award winning Tyko Project, a high-grade sulphide, copper-nickel project located in Canada. Follow Palladium One on LinkedInTwitter, and at www.palladiumoneinc.com.

ON BEHALF OF THE BOARD
“Derrick Weyrauch”
President & CEO, Director

For further information contact:
Derrick Weyrauch, President & CEO
Email: info@palladiumoneinc.com

Neither the TSX Venture Exchange nor its Market Regulator (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States of America. The common shares of Palladium One Mining Inc. have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

Information set forth in this press release may contain forward-looking statements. Forward-looking statements are statements that relate to future, not past events. In this context, forward-looking statements often address a company’s expected future business and financial performance, and often contain words such as “anticipate”, “believe”, “plan”, “estimate”, “expect”, and “intend”, statements that an action or event “may”, “might”, “could”, “should”, or “will” be taken or occur, or other similar expressions. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; fluctuations in palladium and other commodity prices; title matters; environmental liability claims and insurance; reliance on key personnel; the absence of dividends; competition; dilution; the volatility of our common share price and volume; and tax consequences to Canadian and U.S. Shareholders. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date that statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change. Investors are cautioned against attributing undue certainty to forward-looking statements.

Two-Phase Immune System Stimulation to Treat Cancer


Image Courtesy of MIT Research

Checkpoint Blockade Inhibitors Combined With Immune System Stimulation to Fight Cancer

 

Anne Trafton | MIT
News Office

Stimulating the body’s immune system to attack tumors is a promising way to treat cancer. Scientists are working on two complementary strategies to achieve that: taking off the brakes that tumors put on the immune system; and “stepping on the gas,” or delivering molecules that jumpstart immune cells.

However, when jumpstarting the immune system, researchers have to be careful not to overstimulate it, which can cause severe and potentially fatal side effects. A team of MIT researchers has now developed a new way to deliver a stimulatory molecule called IL-12 directly to tumors, avoiding the toxic effects that can occur when immunostimulatory drugs are given throughout the body.

 

“Even beyond this particular case of IL-12, which we
really hope will have some impact, it’s a strategy that you could apply to any
of these immunostimulatory drugs,”
– Darrell Irvine, member of the Ragon Institute of MGH, MIT, and Harvard.

 

In a study of mice, this new treatment eliminated many tumors when delivered along with an FDA-approved drug that takes the brakes off the immune system.

“Even beyond this particular case of IL-12, which we really hope will have some impact, it’s a strategy that you could apply to any of these immunostimulatory drugs,” says Darrell Irvine, who is the Underwood-Prescott Professor with appointments in MIT’s departments of Biological Engineering and Materials Science and Engineering; an associate director of MIT’s Koch Institute for Integrative Cancer Research; and a member of the Ragon Institute of MGH, MIT, and Harvard.

The researchers have filed for patents on their strategy, and the technology has been licensed to a startup that hopes to begin clinical trials by the end of 2022.

Irvine and Dane Wittrup, the Carbon P. Dubbs Professor of Chemical Engineering and Electrical Engineering and a member of the Koch Institute, are the senior authors of the study, which appears today in Nature Biomedical Engineering. MIT graduate student Yash Agarwal is the paper’s lead author.

 

Stepping on the Gas

As tumors develop, they secrete molecules that disable nearby T-cells and other immune cells, allowing the tumors to grow unchecked. Drugs known as checkpoint blockade inhibitors, which can take these brakes off the immune system, are now used to treat some types of cancer, but many other types are resistant to this kind of treatment.

Combining checkpoint inhibitors with drugs that stimulate the immune system could potentially make cancer immunotherapy work for more patients. Cytokines, which are immune chemicals naturally produced by the body, are one class of drugs that researchers have tried as a way to “step on the gas.” However, in clinical trials, these drugs have shown too many toxic side effects, ranging from flu-like symptoms to organ failure.

“If you soak the patient in cytokines, their whole body reacts and you get such a strong, toxic side effect that you can’t reach the levels you wish you could within the tumor and get the effects that you want,” Wittrup says.

To try to avoid those side effects, Wittrup and Irvine have been working on ways to deliver cytokines in a more targeted way. In a 2019 study, they showed that they could deliver the cytokines IL-12 and IL-2 directly to tumors by attaching the cytokines to a collagen-binding protein. This protein then sticks to collagen found in tumors, which usually have large amounts of collagen.

This strategy worked well in a study of mice, but the researchers wanted to find a way to make cytokines bind even more strongly to tumors. In their new study, they replaced the collagen-binding protein with aluminum hydroxide. This compound, also called alum, is often used as a vaccine adjuvant (a drug that helps boost the immune response to vaccination).

“One major advantage of alum is that the particles are on the micron size scale, so when you inject them in people or in mice, they stay wherever you inject them for weeks, going on to months sometimes,” Agarwal says.

 

Fighting Tumors

To test the effectiveness of this treatment, the researchers gave mice one injection of IL-12 or IL-2 bound to alum particles, and treated the mice with a checkpoint blockade inhibitor called anti-PD1 every few days.

In mouse models of three types of cancer, the researchers found that the tumors were eliminated in 50 to 90 percent of the mice. In a model where breast cancer cells were transplanted into mice, and then metastasized to the lungs, one injection at the breast cancer site also cleared the metastatic tumors, even though IL-12 was not injected into the lungs.

Alum-IL-12 particles given without the checkpoint blockade inhibitors also showed some ability to stimulate the immune system to fight tumors.

Further studies showed that IL-12 stimulates the production of another cytokine called interferon gamma, and these two molecules work together to activate T cells as well as dendritic cells and macrophages. The treatment also stimulates memory T cells that may be able to respond to tumors that regrow.

The researchers also found that the treated mice did not show any of the side effects that are seen when IL-12 is given systemically. The startup company that has licensed the technology plans to first test IL-12-alum particles on their own, and if that treatment is shown to be safe, they hope to test Il-12 in combination with checkpoint blockade inhibitors.

The new approach of attaching molecules to alum could also be used to deliver other types of immunostimulatory drugs, the researchers say.

“This whole class of drugs that involves stepping on the gas has largely not succeeded yet. Our hope is that this opens the way to test any of those drugs,” Irvine says.

Suggested Content



Cocrystal Pharma Virtual Roadshow (Video)



Lineage Cell Therapeutics C-Suite Interview (Video)





Three Innovative Platforms That Could Change Cancer Treatment



Why They Use Antibiotics on the Covid Virus

 

This article originally appeared in MIT News on January 10, 2022 and has been Shared with Permission

 

Stay up to date. Follow us:

 

Release – Voyager Digital CEO Withdraws Automatic Securities Disposition Plan

 



Voyager Digital CEO Withdraws Automatic Securities Disposition Plan

Research, News, and Market Data on Voyager Digital

 

Voyager Digital Ltd. (“Voyager” or the “Company”) (TSX: VOYG; OTCQB: VYGVF; FRA: UCD2) one of the fastest-growing, publicly traded cryptocurrency platforms in the United States, today announced that Stephen Ehrlich, CEO and Director, has withdrawn the automatic securities disposition plan (“ASDP”) that was previously announced on December 31, 2021. No shares have been sold under the plan. The ASDP will, in accordance with its terms, terminate 30 days from the date of this press release.
 
Commenting on the withdrawal, Mr. Ehrlich noted, “Despite having a floor significantly above the current stock price, I felt it was in the best interest of the investors to withdraw the plan.” Ehrlich continued, “Based on our key financial metrics, including revenues for the quarter ended December 31, 2021 as disclosed in our press release issued January 5, 2022, I believe Voyager is undervalued and am excited about our product growth and expanded capabilities planned for 2022, including our NFT offering, debit card rollout, international expansion and more.
 
About Voyager Digital Ltd.

Publicly traded Voyager Digital Ltd.’s (TSX: VOYG) (OTCQB: VYGVF) (FRA: UCD2) US subsidiary, Voyager Digital, LLC, is a fast-growing, cryptocurrency platform in the United States founded in 2018 to bring choice, transparency, and cost efficiency to the marketplace. Voyager offers a secure way to trade over 70 different cryptocurrency assets using its easy-to-use mobile application and earn rewards up to 12% annually on more than 35 cryptocurrencies. Through its subsidiary Coinify ApS, Voyager provides cryptocurrency payment solutions for both consumers and merchants around the globe.

To learn more about the company, please visit https://www.investvoyager.com.

The TSX has not approved or disapproved of the information contained herein.

SOURCE Voyager Digital, Ltd.

Press Contacts

Voyager Digital, Ltd.

Michael Legg
Chief Communications Officer
(212) 547-8807
mlegg@investvoyager.com

Voyager Public Relations Team
pr@investvoyager.com

Wall Streets Tools to Copycat Meme Stock Investor Successes


Is it Game-Over for Meme Stock Investors?

 

The tide turned about a year ago.  Professional traders scoffed at the activity they were witnessing in presumed “dead” stocks.  GameStop (GME), AMC Theaters (AMC), both skyrocketing.  Even presumed pandemic nightmare companies such as Hertz (HTZ), international bulk carrier Seanergy (SHIP), and  Norwegian Cruise Lines (NCLH) saw unexpected
buy interest
from self-directed investors.  TV pundits discussed how the retail traders placing these trades were going to get wiped out.  Meanwhile, retail’s combined activity hurt the value of a few powerful funds, notably those that had massive shorts in some of these companies.  Their activity even caused retail brokers like E*Trade (MS) and Robinhood (HOOD) to
halt
some activities
in the popular retail shares.  It used to be that small investors tried to mimic the professionals.  Now, tools are being created so the big guys can monitor communication, sentiment, and activity on social media platforms such as Reddit, Twitter (TWTR), and Stocktwits.

Money Flows

Economics 101 tells us prices move up when demand increases with unchanged supply.  This is just as true for stocks as it is for Gold,
oil, or even tulip
bulbs
.  By the same math, there are worthwhile companies whose value is not yet recognized that would likely be priced higher with more attention.  And companies with extremely unpredictable tomorrows that, if the masses all moved to buy at once, would surely see a price increase.  

A number of hedge funds that underestimated the tenacity of the r/wallstreetbets traders, were resolved to hold their short positions while the retail demand was increasing.  In the end, it’s calculated that managed funds lost $20 billion in this Davey vs. Goliath match-up.

These money flows, possibly even stimulus
check
 funded accounts, “left a mark” on institutional investors.  No previous experience or education prepared them for this phenomenon.  Prices of fallen-from-favor household name stocks were soaring by hundreds of a percent.  Their experience instead indicated they should side against the amateurs.

 

Change of Thinking

As it became widely known that retail traders or amateur investors plotting on social media and message boards were capable of running-up stocks or commodities, the pros took a “game-on” stance.  It was a game they didn’t win, beaten down companies like GameStop rose 2,000% in the face of pros shorting the stock.

 

“If enough people with enough money start valuing stocks a different way, their new metrics matter, too, even if you think they’re absurd,” – Jim Kramer, discussing the climb in Wendy’s (WND) shares, June 8, 2021.

 

After almost a year, professionals are recognizing that the market’s climate has changed, and they should amass the tools they need to combat the new environment.  A company called Sentifi, with the tagline “Better Investments With Collective
Intelligence,”
has just signed a deal to provide “alternative data” to Morningstar.  The company keeps track of hundreds of millions of messages across social media websites like Twitter and Reddit.  It observes shifts in chatter that can help predict which companies or assets are about to soar or plummet.  Morningstar which is one of the most broadly followed investment analytics providers will be integrating Sentifi’s sentiment and attentive analytics into its products as an additional toolset.  The intent is to provide users, including fund managers, financial advisors, and other investors, a means to keep pace with market shifts and price signals.  The expectation is to uncover shifts in sentiment early, discern investment opportunities and risks inherent in the changes.  

While Morningstar is integrating Sentifi into its product line, many other companies, particularly hedge funds, began to rely on its analysis last year.  Other large firms have built their own data gathering information systems.  At UBS, analysts now monitor retail trading activity; in-house traders use the information as one of their decision-making tools.  The investment bank directly tracks retail flows and volumes, analyzes options activity, and monitors social-media sentiment to determine the strength of what self-directed investors may be doing.  Keith Parker is the head of US equity strategy at UBS, he has said, “For the most part, retail doesn’t impact or traffic in tons of stocks.  But the ones that they do, they tend to have pretty outsized influence.  And so it does matter at the extremes.”

 

Take-Away

As the expression goes, kill or be killed.  As the markets evolve, so must the players in order to continue to interact with the market.  An increasing number of professionals are not just taking retail stock market activity seriously; they are committed to benefitting from it.  The benefit can be both offensive and defensive.  It remains to be seen if the offensive plays that could be categorized as joining with the retail action will induce even more pronounced swings, but it is clear that information is readily available to them as the so-called meme stock investors are effectively writing their plays out where they can be seen and studied.  Their tactics may need to be altered.

Paul Hoffman

Managing Editor, Channelchek

 

Suggested Reading



You Can Own a Piece of r/WallStreetBets



Tulip Mania Compared to Cryptocurrencies and Meme Stock Investing





Short-Sellers Vs. GameStop Buyers



Are Meme Stocks Improving Flawed Markets?

 

 

Sources

https://www.youtube.com/watch?v=aSUuB4cLWPU

https://www.morningstar.com/news/business-wire/20211208005489/sentifi-announces-addition-of-alternative-data-into-morningstar-data-products

 

Stay up to date. Follow us:

 

Endeavour Silver Provides 2022 Guidance, Including Production of 4.2-4.8 Million oz Silver and 31,000-35,000 oz Gold for 6.7-7.6 Million oz Silver Equivalent



Endeavour Silver Provides 2022 Guidance, Including Production of 4.2-4.8 Million oz Silver and 31,000-35,000 oz Gold for 6.7-7.6 Million oz Silver Equivalent

Research, News, and Market Data on Endeavour Silver

 

VANCOUVER, British Columbia, Jan. 20, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to announce its consolidated production and cost guidance as well as its capital and exploration budgets for 2022. All dollar amounts are in US dollars (US$).

2022 Production and Cost Guidance Highlights

In 2022, silver production is expected to range from 4.2 to 4.8 million ounces (oz) and gold production is anticipated to be between 31,000 oz and 35,000 oz. Silver equivalent production is forecasted to total between 6.7 million and 7.6 million oz at an 80:1 silver:gold ratio.

Consolidated cash costs 2 and all-in sustaining costs 2 (“AISC”) in 2022 are estimated to be $9.00-$10.00 per oz silver and $20.00-21.00 per oz silver, respectively, net of gold by-product credits. The Company’s 2022 cost outlook is higher than the prior year as inflation, royalties and mining duties are expected to increase in 2022.

“Our operations outperformed last year with Guanacevi’s production bolstered by higher than anticipated mined ore grades,” stated Dan Dickson, Endeavour’s CEO. “In 2022, our production outlook is on par with the average of the last three years as we anticipate the grade at Guanacevi to be more in line with our estimated reserves and we remove the small annual contribution from our El Compas mine, which closed last August.”

Mr. Dickson added, “This year, the team is focused on managing costs in order to offset the inflationary pressures we are seeing across the industry. Equally important will be expanding resources and advancing our exceptional growth pipeline. Terronera will move from the funding and approval phase through to construction. As well, we will initiate a preliminary economic assessment at Parral and define a current resource at Pitarrilla following the closing of this acquisition in the first half of the year.”

2022 Guidance Summary

    Guanacevi Bolanitos Consolidated
Tonnes per day tpd 1,100 – 1,200 1,000 – 1,200 2,100 – 2,400
Silver production M oz 3.8 – 4.2 0.4 – 0.6 4.2 – 4.8
Gold production k oz 10.0 – 12.0 21.0 – 23.0 31.0 – 35.0
Silver Eq production 1 US$/oz 4.6 – 5.2 2.1 – 2.4 6.7 – 7.6
Cash costs, net of gold by-product credits 2 US$/oz     $9.00 – $10.00
AISC, net of gold by-product credits 2 US$/oz     $20.00 – $21.00
Sustaining capital 2 budget US$M     $34.3
Development budget US$M     $11.5
Exploration budget US$M     $13.0

Operating Mines

At Guanaceví, 2022 production will range from 1,100 tonnes per day (tpd) to 1,200 tpd and average 1,165 tpd from the Milache, SCS and P4E orebodies. A significant portion of production will be mined from the Porvenir Cuatro extension on the El Curso concessions. The El Curso concessions were leased from a third party with no upfront costs but with significant royalty payments on production. Compared to 2021, ore grades are expected to decrease slightly with similar recoveries. Cash costs per ounce and direct operating costs per tonne are expected to increase in 2022, primarily due to the impact of inflation on power costs, re-agent costs and salaries as well as higher estimated royalty and mining duty payments.

In 2022, production at Bolañitos is expected to range from 1,000 tpd to 1,200 tpd and average 1,080 tpd from the Plateros-La Luz, Lucero-Karina and Bolanitos-San Miguel vein systems. Ore grades and recoveries are expected to be similar to 2021. Cash costs per oz and direct costs per tonne are expected to increase primarily due to inflationary impact on power costs and salaries.

Operating Costs

In 2022, cash costs, net of gold by-product credits, are expected to be $9.00-$10.00 per oz of silver produced. Consolidated cash costs on a co-product basis 2 are anticipated to be $13.00-$14.00 per oz silver and $1,100-$1,200 per oz gold.

All-in sustaining costs, net of gold by-product credits, in accordance with the World Gold Council standard, are estimated to be $20.00-$21.00 per oz of silver produced. When non-cash items such as stock-based compensation and accretion are excluded, AISC are forecast to be in the $19.00-$20.00 range.

Direct costs 2 per tonne are estimated to be $95-$100 with inflationary pressures expected to continue in 2022. Direct operating costs 2 , which includes royalties and special mining duties are estimated to be in the range of $120-$125 per tonne.

Management made the following assumptions in calculating its 2022 cost forecasts: $22 per oz silver price, $1,760 per oz gold price, and 20:1 Mexican peso per US dollar exchange rate.

2022 Capital Budget

  Mine
Development
Other
Capital
Sustaining
Capital
Growth
Capital
Total
Capital
Guanaceví $10.3 million $10.1 million $20.4 million $20.4 million
Bolañitos $8.4 million $3.8 million $12.2 million $12.2 million
Terronera $9.5 million $9.5 million
Corporate $1.7 million $2.0 million $3.7 million
Total $18.7 million $13.9 million $34.3 million $11.5 million $45.8 million

Sustaining Capital Investments

In 2022, Endeavour plans to invest $34.3 million in sustaining capital, including $32.6 million at its two operating mines and $1.7 million to maintain exploration concessions and cover corporate infrastructure. At current metal prices, the sustaining capital investments are expected to be paid out of operating cash flow.

At Guanacevi, $20.4 million will be invested in capital projects, the largest of which is the development of 5.7 kilometres of mine access at the Milache, SCS and the P4E orebodies for an estimated $10.3 million. The additional $10.1 million will go to upgrade the mining fleet, support site infrastructure and expand the tailings dam.

At Bolañitos, $12.2 million will be invested in capital projects, including $8.4 million for 5.5 kilometres of mine development to access resources in the Plateros-La Luz, Lucero-Karina, Bolanitos-San Miguel and Belen vein systems. The additional $3.8 million will go to upgrade the mining fleet, support site infrastructure, raise the tailings dam and commence a new portal to access the Belen ore body.

At Terronera, $9.5 million is budgeted for the first quarter of 2022 to continue with final detailed engineering, early earth works, critical contracts and procurement of long lead items. The Company intends to make a formal construction decision, subject to completion of a financing package and receipt of amended permits, in the coming months, at which time the budget for the remainder of 2022 for the project will be determined.

The capital budget presented above does not include the $70 million acquisition cost associated with the Company’s recently announced acquisition of the Pitarrilla Project ( see January 13, 2022 news release ) in Durango State, Mexico from SSR Mining Inc. The transaction is expected to be completed in the first half of 2022.

2022 Exploration Budget

Project 2022 Activity Drill Metres Expenditures
Guanaceví Drilling 11,000 $1.8 million
Bolañitos Drilling 10,000 $1.5 million
Terronera Drilling 11,000 $1.9 million
Parral Drilling/Economic Study 7,000 $1.7 million
Chile – Aida Drilling 3,000 $1.5 million
Chile – Other Evaluation $0.9 million
Bruner Drilling/Evaluation 3,000 $1.9 million
Pitarrilla Drilling/Evaluation 5,000 $1.8 million
Total   50,000 $13.0 million

In 2022, the Company plans to spend $13.0 million drilling 50,000 metres across its properties.

At the Guanacevi and Bolanitos mines, 21,000 metres of drilling are planned at a cost of $3.3 million to replace reserves and expand resources.

At the Terronera development project, 11,000 metres are planned to test multiple regional targets identified in 2021 to expand resources within the district.

At the Parral project in Chihuahua state, 7,000 metres are planned at a cost of $1.7 million to delineate existing resources, expand resources and test new targets. In the second half of the year, the Company expects to initiate a preliminary economic assessment.

In Chile, management intends to invest $1.5 million to test the Aida exploration project located in the northern Chile Region II along the Argentina border accessible by paved highway and dirt road. The Company plans to drill 3,000 metres to test a manto target with significant silver-manganese-lead-zinc anomaly at surface in the second half of 2022. Additionally, the Company plans to advance mapping, sampling and surface exploration on its other exploration projects in Chile, estimated to cost $0.9 million including administration costs in the country.

At the Bruner project management plans to invest $1.9 million to evaluate and verify historical data to define a current resource, map and sample new targets and drill 3,000 metres verifying historical data and testing new targets.

Similarly, subject to closing the Pitarrilla acquisition, management plans to invest $1.8 million for drilling to verify the historical data and define a current resource in 2022. Management plans to release a more detailed exploration and evaluation plan for the Pitarrilla project following closing of the transaction.

About Endeavour Silver – Endeavour Silver Corp. is a mid-tier precious metals mining company that operates two high-grade underground silver-gold mines in Mexico. Endeavour is currently advancing the Terronera mine project towards a development decision, pending financing and final permits and exploring its portfolio of exploration and development projects in Mexico, Chile and the United States to facilitate its goal to become a premier senior silver producer.  Our philosophy of corporate social integrity creates value for all stakeholders.

SOURCE Endeavour Silver Corp.

Contact Information
Trish Moran
Interim Head of Investor Relations
Tel: (416) 564-4290
Email: pmoran@edrsilver.com
Website: www.edrsilver.com

Follow Endeavour Silver on Facebook Twitter Instagram and LinkedIn

Endnotes

1 Silver equivalent is calculated using an 80:1 silver:gold ratio.

Non-IFRS Financial Measures

The Company has included certain performance measures that are not defined under International Financial Reporting Standards (“IFRS”). The Company believes that these measures, in addition to conventional measures prepared in accordance with IFRS, provide investors an improved ability to evaluate the underlying performance of the Company. The non-IFRS measures are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. These measures do not have any standardized meaning prescribed under IFRS, and therefore may not be comparable to other issuers.

Cash costs and cash costs per ounce

Cash costs per ounce is a non-IFRS measure. In the silver mining industry, this metric is a common performance measure that does not have a standardized meaning under IFRS. Cash costs include direct costs (including smelting, refining, transportation and selling costs), royalties and special mining duty and changes in finished goods inventory net of gold credits. Cash costs per ounce is based on ounces of silver produced and is calculated by dividing cash costs by the number of ounces of silver produced.

Cash costs on a co-product and cash costs on a co-product per ounce

Silver co-product cash costs and gold co-product cash costs include mining, processing (including smelting, refining, transportation and selling costs), and direct overhead costs allocated on pro-rated basis of realized metal value. Cash costs on a co-product per ounce is based on the number of either silver or gold ounces produced.

Direct operating costs and direct costs

Direct operating costs per tonne include mining, processing (including smelting, refining, transportation and selling costs) and direct overhead at the operation sites. Direct costs per tonne include all direct operating costs, royalties and special mining duty.

All-in sustaining costs (“AISC”) and AISC per ounce

This measure is intended to assist readers in evaluating the total cost of producing silver from operations. While there is no standardized meaning across the industry for AISC measures, the Company’s definition conforms to the definition of AISC as set out by the World Gold Council and used as a standard of the Silver Institute. The Company defines AISC as the cash costs (as defined above), plus reclamation cost accretion, mine site expensed exploration, corporate general and administration costs and sustaining capital expenditures. AISC per ounce is based on ounces of silver produced and is calculated by dividing AISC by the number of ounces of silver produced.

Sustaining capital

Sustaining capital is defined as the capital required to maintain operations at existing levels. This measurement is used by management to assess the effectiveness of an investment program.

For further information on reconciliations of Non-GAAP measures, refer to the Non-IFRS Measures section of the Company’s Management’s Discussion & Analysis for the three and nine months ending September 30, 2021, beginning on page 19.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the United States private securities litigation reform act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include but are not limited to statements regarding Endeavour’s anticipated performance in 2022 including changes in mining operations and forecasts of production levels, anticipated production costs and all-in sustaining costs, the timing and results of various activities and the impact of the COVID 19 pandemic on operations. The Company does not intend to and does not assume any obligation to update such forward-looking statements or information, other than as required by applicable law.

Forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, production levels, performance or achievements of Endeavour and its operations to be materially different from those expressed or implied by such statements. Such factors include but are not limited to the ultimate impact of the COVID 19 pandemic on operations and results, changes in production and costs guidance, national and local governments, legislation, taxation, controls, regulations and political or economic developments in Canada and Mexico; financial risks due to precious metals prices, operating or technical difficulties in mineral exploration, development and mining activities; risks and hazards of mineral exploration, development and mining; the speculative nature of mineral exploration and development, risks in obtaining necessary licenses and permits, and challenges to the Company’s title to properties; as well as those factors described in the section “risk factors” contained in the Company’s most recent form 40F/Annual Information Form filed with the S.E.C. and Canadian securities regulatory authorities.

Forward-looking statements are based on assumptions management believes to be reasonable, including but not limited to: the continued operation of the Company’s mining operations, no material adverse change in the market price of commodities, mining operations will operate and the mining products will be completed in accordance with management’s expectations and achieve their stated production outcomes, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or information, there may be other factors that cause results to be materially different from those anticipated, described, estimated, assessed or intended. There can be no assurance that any forward-looking statements or information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements or information. Accordingly, readers should not place undue reliance on forward-looking statements or information.